Partnership between AstraZeneca and the Ó³»­´«Ã½

AstraZeneca and the Ó³»­´«Ã½ in Cambridge, Massachusetts have announced a collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs (see the joint press release here. Dr. Michael Foley, director of the Ó³»­´«Ã½'s Chemical Biology Platform and Dr. Manos Perros, vice president and head of the Infection Innovative Medicines Unit describe the partnership in this video.